Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Nilo Post-STIM
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 Planned End Date changed from 1 Apr 2020 to 1 Dec 2021.
- 29 Oct 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2021.